KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
101 hedge funds and large institutions have $349M invested in KalVista Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 10 closing their positions.
165% more call options, than puts
Call options by funds: $10.8M | Put options by funds: $4.06M
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
13% more capital invested
Capital invested by funds: $310M → $349M (+$39.2M)
7% more funds holding
Funds holding: 94 → 101 (+7)
4.59% more ownership
Funds ownership: 100.82% → 105.42% (+4.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$9.2M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$8.06M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$4.07M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$3.95M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$5.02M |
| 2 |
CC
Commodore Capital
New York
|
-$2.81M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.25M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.88M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$975K |
KALV Hedge Fund Activity: Q3 2023 in Review
101 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2023, worth a combined $349M — up 13% from $310M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KALV positions and 10 closed out — a net gain of 7 holders — while 34 added to existing stakes and 27 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $9.2M. The largest seller was Silverarc Capital Management, cutting an estimated $5.02M.
- 101 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2023, up from 94 in Q2 2023.
- Funds reported $349M of KalVista Pharmaceuticals stock for Q3 2023, up 13% quarter-over-quarter.
- 17 funds opened new KalVista Pharmaceuticals positions in Q3 2023 and 10 closed out, a net change of +7 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2023 was Logos Global Management, an estimated $9.2M added.
- The largest KalVista Pharmaceuticals seller in Q3 2023 was Silverarc Capital Management, an estimated $5.02M sold.
Based on aggregated 13F filings for Q3 2023.